Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.”In the company’s words, NCT06241781 on ClinicalTrials.gov
Other drugs for Recurrent or Metastatic Cervical Cancer
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up1
- 31 Jan 2027Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT05430373
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Jan 2027 | Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer | |
| Phase 1Active, not recruiting | 25 Sep 2025 | GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026